B · Normal
[Leadman: Subsidiary's recombinant group B meningococcal vaccine starts Phase I clinical trial] On November 17, Leadman (300289.SZ) announced that the company's holding subsidiary Simcere Xiangrui independently developed the recombinant group B meningococcal vaccine that has launched a phase I clinical trial at the Hunan Provincial Center for Disease Control and Prevention. This vaccine uses recombinant protein technology and is used to prevent epidemic cerebrospinal meningitis caused by group B meningococci. No similar product has been approved for marketing in China. This phase I clinical trial is a randomized, blinded, placebo-controlled design, aiming to evaluate the safety, tolerability and preliminary immunogenicity of the vaccine in people aged 3 months and above. The company reminds that the drug development cycle is long and the risks are high. The trial will not have a significant impact on recent performance, and there is uncertainty in subsequent progress.
A-share announcement express 🕐 2026-11-17 18:09

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet